Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | DRD4 | P21917 | 3/20 | 0.34 |
| ▸ | DRD3 | P35462 | 3/20 | 0.34 |
| ▸ | HTR1A | P08908 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | KDM4A | O75164 | 1/20 | 0.32 |
| ▸ | KDM4B | O94953 | 1/20 | 0.32 |
| ▸ | KDM5C | P41229 | 1/20 | 0.32 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.32 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2611049 | 0.74 | PARP1 (0.46) | ALDH1A1PARP1BRD4DRD4DRD3 | |
| SCHEMBL20032408 | 0.73 | PARP1 (0.42) | ALDH1A1PKMPARP1BRD4DRD4 | |
| SCHEMBL2817256 | 0.72 | PARP1 (0.54) | ALDH1A1PKMPARP1BRD4 | |
| SCHEMBL18713659 | 0.72 | TSHR (0.42) | ALDH1A1PKMPARP1BRD4DRD4 | |
| SCHEMBL24351926 | 0.71 | PARP1 (0.44) | ALDH1A1PARP1BRD4DRD4DRD3 | |
| SCHEMBL7856459 | 0.71 | PARP1 (0.47) | ALDH1A1PKMPARP1BRD4DRD4 | |
| SCHEMBL2127994 | 0.71 | HTR2A (0.47) | PARP1BRD4DRD4DRD3DRD2 | |
| SCHEMBL2142149 | 0.70 | ALDH1A1 (0.53) | ALDH1A1PKMPARP1BRD4DRD4 | |
| SCHEMBL2127998 | 0.69 | PARP1 (0.41) | PARP1BRD4DRD4DRD3DRD2 | |
| SCHEMBL31693421 | 0.68 | HTR2A (0.47) | ALDH1A1PKMPARP1DRD3HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2424843-B1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF CYCLIN DEPENDENT KINASES | NOVARTIS AG (CH) | 2014-03-26 | — | — | EP | disclosed |
| US-8598217-B2 | Imidazole derivatives and their use as modulators of cyclin dependent kinases | ASTEX THERAPEUTICS LTD. (GB) | 2013-12-03 | — | — | US | disclosed |
| US-20120101064-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF CYCLIN DEPENDENT KINASES | ASTEX THERAPEUTICS LIMITED (GB) | 2012-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101064-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF CYCLIN DEPENDENT KINASES | CDK3, CCNI, CDK1 | ALDH1A1 3598/4885PKM 564/4885PARP1 1929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.